87427-58-5

Basic information

• Product Name: 2-Bromo-1-(3-bromo-4-chlorophenyl)ethanone
• Synonyms: 2-Bromo-1-(3-bromo-4-chlorophenyl)ethanone
• CAS NO: 87427-58-5
• Molecular Formula: C₈H₅Br₂ClO
• Molecular Weight: 312
• Mol File: 87427-58-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.924
• CAS DataBase Reference: 2-Bromo-1-(3-bromo-4-chlorophenyl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-1-(3-bromo-4-chlorophenyl)ethanone(87427-58-5)
• EPA Substance Registry System: 2-Bromo-1-(3-bromo-4-chlorophenyl)ethanone(87427-58-5)

Safety Data

• Hazardous Substances Data: 87427-58-5(Hazardous Substances Data)

Usage

General Description

2-Bromo-1-(3-bromo-4-chlorophenyl)ethanone is a chemical compound with the molecular formula C8H6Br2ClO. It is a halogenated ketone that is commonly used as a precursor in the synthesis of pharmaceuticals and organic compounds. 2-Bromo-1-(3-bromo-4-chlorophenyl)ethanone is a pale yellow solid with a faint odor and is insoluble in water but soluble in organic solvents. It is primarily used in organic chemistry research and as an intermediate in the production of various chemicals. It is important to handle this compound with caution and in accordance with safety guidelines, as it is considered harmful if swallowed or inhaled, and can cause skin and eye irritation.

Upstream product

• 54826-14-1 1-(3-bromo-4-chlorophenyl)ethan-1-one 

Relevant articles and documents

Discovery of Novel UDP- N-Acetylglucosamine Acyltransferase (LpxA) Inhibitors with Activity against Pseudomonas aeruginosa

This study describes a novel series of UDP-N-acetylglucosamine acyltransferase (LpxA) inhibitors that was identified through affinity-mediated selection from a DNA-encoded compound library. The original hit was a selective inhibitor of Pseudomonas aeruginosa LpxA with no activity against Escherichia coli LpxA. The biochemical potency of the series was optimized through an X-ray crystallography-supported medicinal chemistry program, resulting in compounds with nanomolar activity against P. aeruginosa LpxA (best half-maximal inhibitory concentration (IC50) 20 μM and MIC > 128 μg/mL). The mode of action of analogues was confirmed through genetic analyses. As expected, compounds were active against multidrug-resistant isolates. Further optimization of pharmacokinetics is needed before efficacy studies in mouse infection models can be attempted. To our knowledge, this is the first reported LpxA inhibitor series with selective activity against P. aeruginosa.

IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY

Provided are the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.

Synteza zwiazkow o potencjalnym dzialaniu radiouczulajacym. VII. Synteza alkiloksantogenianow 3-bromo-4-chlorofenacylowych

In the frame-work of search for new potential radiosensitizers a series novel 3-bromo-4-chlorophenacyl alkylxanthates were synthesized by reacting 3-bromo-4-chlorophenacyl bromide with potassium alkylxanthates, in which allyl, ethyl, propyl, isopropyl, bu